Agraphis Mutans Granule 1dh-30dh 1 Dh Tablet is a Health Canada–registered human drug (DIN 01933086) held by Homeocan Inc., containing Agraphis Nutans. Health Canada lists its status as Cancelled Post Market (status date 15 Oct 1997). Nexara Health has matched 12 registrations of Agraphis Nutans across 2 other regulated markets.
Health Canada registration
| DIN | 01933086 |
|---|---|
| Brand name | Agraphis Mutans Granule 1dh-30dh |
| Active ingredient | Agraphis Nutans |
| Strength | 1 Dh |
| Dosage form | Tablet |
| Route | Oral |
| Company | Homeocan Inc. |
| Status | Cancelled Post Market — 15 Oct 1997 |
| Class | Human |
| ATC | |
| AHFS | 92:02.00* ; See footnote |
| Regulator record | Health Canada DPD entry · Product monograph |
Agraphis Nutans registered in other markets
12 registrations of the same molecule in 2 national registries outside Canada (first 10 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| Netherlands | Agraphis nutans | BOIRON (Messimy) | 4 DH t/m 60 DH#2 CH t/m 200 CH#6 K t/m 100.000 K#1 LM t/m 30 LM | Uitsluitend apotheek of drogist | EU national register | |
| Netherlands | Agraphis nutans | BOIRON (Messimy) | 4 DH t/m 60 DH#2 CH t/m 200 CH#6 K t/m 100.000 K#1 LM t/m 30 LM | Globuli | Uitsluitend apotheek of drogist | EU national register |
| United States | Agraphis nutans | Hahnemann Laboratories, Inc. | Pellet | listed | FDA NDC | |
| United States | Agraphis nutans | Hahnemann Laboratories, Inc. | Pellet | listed | FDA NDC | |
| United States | Agraphis Nutans | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Agraphis Nutans | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Agraphis Nutans | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Agraphis Nutans | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Agraphis Nutans | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Agraphis Nutans | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC |
See every manufacturer of Agraphis Nutans worldwide →
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. This DIN is not currently marketed in Canada. The registrations above show which regulated markets hold an equivalent presentation that can be sourced for clinical comparator use or on a named-patient basis under Health Canada's Special Access Programme. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Agraphis Mutans Granule 1dh-30dh (DIN 01933086) marketed in Canada?
No. Health Canada lists DIN 01933086 as Cancelled Post Market as of 15 Oct 1997.
Who holds the Canadian licence for this product?
Homeocan Inc. is the company of record in the Health Canada Drug Product Database.
Is Agraphis Nutans registered outside Canada?
Yes — Nexara Health has matched 12 registrations in 2 other markets (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 01933086, status date 1997-10-15; national medicine registries: EU national register, FDA NDC. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 01933086, status date 1997-10-15; national medicine registries: EU national register, FDA NDC.
Health Canada Drug Product Database (DPD), DIN 01933086, status date 1997-10-15; national medicine registries: EU national register, FDA NDC. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.